TER

Teradyne

Q1 FY2026 earnings · 2026-04-27$2.12 consensus

Summary

What they do:

Build automated test equipment (ATE) — the machines that test every semiconductor chip after fabrication. Teradyne's systems validate functionality, performance, power delivery, and reliability before any chip ships. Also operates Universal Robots (collaborative robots) and a smaller industrial automation segment.

Why they matter:

Every chip must be tested. AI chips are larger, more complex, and far more expensive than prior generations — driving more test time per chip, more sophisticated test requirements, and more ATE spend. Teradyne and Advantest control ~80% of the global ATE market. Teradyne is the #2 player and is actively winning back share in high-end compute testing, estimated to capture ~40% of tester market for NVIDIA's Rubin-series GPUs.

Recent performance:

Q4 2025 revenue $1.083B, up 44% YoY. Full year 2025 revenue $3.19B, up 13% YoY. Non-GAAP EPS $3.96 for FY2025. AI-driven demand exceeded 60% of Q4 revenue and is expected to exceed 70% in Q1 2026. Stock up ~78% YTD in 2026.

Our Verdict

Play TypeEstablished
Rel. ValuePremium

Established ATE duopoly play benefiting from AI chip complexity driving more test time per device — quality business at premium valuation with Advantest taking the larger share of AI-specific test.

Structural trends

AI chip complexity scalingrising test time per chipHBM test demandcustom ASIC proliferationchiplet architectures requiring more test points

Structural

81

/ 100

Moat

7/10

ATE duopoly + test program lock-in

AI Exp.

High

~65% AI

Play Type

Established

AI Growth

25-35%

Rel. Value

25

PREMIUM

PriceLIVE

$365.51

-1.25%

Live via Yahoo Finance · refreshes every 5 min

Market Cap

$57.2B

P/E Ratio

105.0

P/S Ratio

17.9x

52W High

$373.00

52W Low

$68.24

52W Chg

435.6%

Beta

1.79

The Catch

Teradyne is a cyclical capital equipment business trading at a growth-tech multiple. At ~50x forward earnings, the stock prices in not just the current AI test supercycle but its continuation and Teradyne's ability to hold or gain share within it. The core risk is not that the thesis is wrong — AI chips genuinely require more testing — but that the cycle is already well understood and well priced. ATE orders can turn quickly: fabs defer test equipment purchases within a single quarter when utilization softens. If hyperscaler capex moderates, or if Advantest defends its NVIDIA share position more effectively than expected, or if the semiconductor cycle simply mean-reverts in late 2026 or 2027, the stock has significant downside from current levels. The robotics segment adds narrative appeal but not yet earnings substance, and it consumes management attention and capital that could otherwise reinforce the core ATE franchise.

If They Win

If Teradyne successfully captures a larger share of AI chip testing — winning back NVIDIA compute test share, dominating the HBM test build-out, and becoming the preferred tester for the wave of custom ASICs from hyperscalers — then the company becomes the quality-control chokepoint for the entire AI chip supply chain. Revenue compounds toward the $6B target model. Gross margins expand to 60%+ as high-complexity AI test programs command premium ASPs. The installed base flywheel accelerates: more data from more AI chip tests improves Teradyne's yield correlation algorithms, which makes their systems more valuable, which locks in customers further. Universal Robots becomes a credible Physical AI platform as factory automation converges with AI-driven decision-making. Teradyne transitions from a cyclical equipment supplier to a structural AI infrastructure compounder — the testing equivalent of what ASML became for lithography.

Not financial advice. All scores generated via AI algorithms using public data.